Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study
- 18 June 2018
- journal article
- research article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 18 (8), 884-893
- https://doi.org/10.1016/s1473-3099(18)30397-9
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2016
- Structures of Ebola virus GP and sGP in complex with therapeutic antibodiesNature Microbiology, 2016
- Risk factors for transmission of Ebola or Marburg virus disease: a systematic review and meta-analysisInternational Journal of Epidemiology, 2015
- Ebola viral load at diagnosis associates with patient outcome and outbreak evolutionJCI Insight, 2015
- The Multiple Roles of sGP in Ebola PathogenesisViral Immunology, 2015
- Ebola virus (EBOV) infection: Therapeutic strategiesBiochemical Pharmacology, 2015
- Clinical Presentation of Patients with Ebola Virus Disease in Conakry, GuineaThe New England Journal of Medicine, 2015
- Clinical Illness and Outcomes in Patients with Ebola in Sierra LeoneThe New England Journal of Medicine, 2014
- Structures of protective antibodies reveal sites of vulnerability on Ebola virusProceedings of the National Academy of Sciences of the United States of America, 2014
- Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal miceProceedings of the National Academy of Sciences of the United States of America, 2014